Clinical Trial Update: PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of PS-341 (bortezomib) in metastatic neuroendocrine tumors has completed enrollment with status reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Carcinoid Tumor
• Islet Cell Tumor

Drugs mentioned

• Velcade (bortezomib) (bortezomib)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Status: COMPLETED